Through the pan-Canadian Pharmaceutical Alliance (pCPA), provinces and territories have developed a new initiative with the Canadian Generic Pharmaceutical Association (CGPA) to significantly reduce the price of some of Canadas most commonly prescribed generic drugs
More than 50 percent of generic drugs
have at most two competitors; for 40 percent of drugs, there is just one manufacturer.
The proposed rule would allow makers of generic drugs
to update product labeling with newly acquired safety information before the FDA's review of the change, in the same way that brand drug makers do.
account for nearly 70% of the total retail prescriptions in Canada.
32) Congress designed the Hatch-Waxman Act to provide access to more cost-efficient generic drugs
by establishing an approval process for all new drugs approved after 1962.
are those not covered by patent protection and are labeled only by their international nonproprietary or generic name.
3%) were of the view that generic drugs
were as safe as the innovator drug (p = 0.
House Energy and Commerce Committee requesting hearings to investigate the rising costs of generic drugs
In such a situation, generic drugs
promise to become a "footboard" for China's pharmaceutical industry.
While people may be uncertain about using generic drugs
initially, research has shown that they are more likely to adhere to treatment when prescribed more affordable generic drugs
The fault lies with his hosts who appear to be blissfully unaware of the work being done on generic drugs
by other panels of the parliament.
According to the minister, 670 generic drugs
on the market are slated for a reduction to ensure that their prices are lower than the prices of corresponding brand names drugs.
Currently, generic drugs
account for 50% to 60% of the drug sales in Europe, whereas in France their share is only 25%, Stephane Joly, head of Cristers laboratory, has recently said.
One way to protect yourself from the unknown risks of new drugs is to request generic drugs
are a proven avenue to lower costs and quality health care, and show increasing acceptance by consumers, physicians and payers, according to a study by the Washington-based Pharmaceutical Care Management Association (PCMA).